Wells Fargo Maintains Overweight on United Therapeutics, Raises Price Target to $703
Wells Fargo analyst Benjamin Burnett maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and raises the price target from $700 to $703.
Share
Why It Matters
A big bank analyst likes United Therapeutics and raised their price guess slightly. This suggests the analyst thinks the company is doing well and has good plans ahead.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.